Wedbush Keeps Their Hold Rating on Zentalis Pharmaceuticals (ZNTL)
Zentalis Pharmaceuticals: Navigating Conflicting Analyst Signals and Insider Sentiment Zentalis Pharmaceuticals (NASDAQ: ZNTL) is currently facing a mixed outlook, with analysts offering differing perspectives and recent insider activity raising questions. While TD Cowen maintains a ‘Buy’ rating, Wedbush recently downgraded the stock to ‘Hold’, setting a price target significantly below its current trading price. Analyst … Read more